

# Training Checklist for Home Administered Subcutaneous Immunoglobulin (SCIg) Infusion Treatment

**Specific steps to be assessed prior to patient/carer considered competent to self-administer medication in a home setting. Number of training sessions can be individualised for patients.**

<b>Patient Name:</b>		<b>Clinician:</b>	
<b>Person Responsible for Infusion:</b>	Patient    Carer    Guardian (Please circle)		<b>Name:</b>

Patient Skills	Introduced		Reinforced		Competency Demonstrated		Competency Mastered	
	Date:		Date:		Date:		Date:	
Competent/Not Yet Competent (C/NYC)	C/NYC	Initials	C/NYC	Initials	C/NYC	Initials	C/NYC	Initials
Describe transportation & storage requirements of specific product								
Define SCIg administration and location of site of infusion								
Listing of appropriate infusion sites and understanding of rotation of sites								
Understanding and demonstrated care of infusion site								
Description of appropriate supplies necessary to complete procedure								
Understanding of pump usage and what to do when not working or if alarm sounds								
Understanding of “push” method as an alternative or when pump is unavailable								

Understanding of how to check product/prepare product and how to report wastage/unused product								
Ability to prepare infusion site and draw up product from single or multiple vials and prime tubing								
Demonstrated insertion of subcutaneous catheter /checking for blood/what actions to take if blood is present								
Demonstrates appropriate aseptic technique								
Demonstrates accurate administration of treatment, and removal and safe disposal of needle								
Demonstrates understanding of safe disposal methods for other medical and general waste								
Demonstrates ability to accurately record infusion treatment information in diary								
Understanding of potential situations/reactions which could result from the infusion								
Understanding of correct management of any reactions to treatment								

Form collated from contributions from Octapharma, Baxter and CSL

Updated August 2025